- Home
- LMNR vs YMAB Comparison
LMNR vs YMAB Comparison
Compare LMNR & YMAB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- LMNR
- YMAB
- Stock Information
- Founded
- LMNR 1893
- YMAB 2015
- Country
- LMNR United States
- YMAB United States
- Employees
- LMNR N/A
- YMAB N/A
- Industry
- LMNR Farming/Seeds/Milling
- YMAB Biotechnology: Pharmaceutical Preparations
- Sector
- LMNR Consumer Staples
- YMAB Health Care
- Exchange
- LMNR Nasdaq
- YMAB Nasdaq
- Market Cap
- LMNR 486.1M
- YMAB 482.4M
- IPO Year
- LMNR N/A
- YMAB 2018
- Fundamental
- Price
- LMNR $26.30
- YMAB $8.28
- Analyst Decision
- LMNR Buy
- YMAB Strong Buy
- Analyst Count
- LMNR 2
- YMAB 10
- Target Price
- LMNR $24.00
- YMAB $21.00
- AVG Volume (30 Days)
- LMNR 46.0K
- YMAB 303.4K
- Earning Date
- LMNR 12-23-2024
- YMAB 11-08-2024
- Dividend Yield
- LMNR 1.14%
- YMAB N/A
- EPS Growth
- LMNR N/A
- YMAB N/A
- EPS
- LMNR 0.29
- YMAB N/A
- Revenue
- LMNR $189,075,000.00
- YMAB $84,553,000.00
- Revenue This Year
- LMNR $7.75
- YMAB $6.46
- Revenue Next Year
- LMNR $16.50
- YMAB $20.68
- P/E Ratio
- LMNR $89.98
- YMAB N/A
- Revenue Growth
- LMNR 6.15
- YMAB N/A
- 52 Week Low
- LMNR $17.37
- YMAB $6.29
- 52 Week High
- LMNR $29.22
- YMAB $20.90
- Technical
- Relative Strength Index (RSI)
- LMNR 45.69
- YMAB 25.63
- Support Level
- LMNR $26.39
- YMAB $9.31
- Resistance Level
- LMNR $26.96
- YMAB $11.10
- Average True Range (ATR)
- LMNR 0.96
- YMAB 0.72
- MACD
- LMNR -0.17
- YMAB -0.09
- Stochastic Oscillator
- LMNR 36.39
- YMAB 7.35
About LMNR Limoneira Co
Limoneira Co is an agribusiness company. The company's operating segments include Fresh Lemons; Lemon Packing; Avocados and Other Agribusiness. It generates maximum revenue from the Fresh Lemons segment.
About YMAB Y-mAbs Therapeutics Inc.
Y-mAbs Therapeutics Inc is a commercial-stage biopharmaceutical company. It is mainly engaged in the development and commercialization of novel, antibody-based therapeutic products for the treatment of cancer. DANYELZA, is the first FDA-approved product of the company which is a recombinant humanized immunoglobulin G, subtype 1k, or IgG1k, monoclonal antibody or mAb that targets ganglioside GD2, which is expressed in various neuroectoderm-derived tumors and sarcomas.